SOMAVERT15mgpoudreetsolvantpourinjectable

SOMAVERT15mgpoudreetsolvantpourinjectable Uses, Dosage, Side Effects, Food Interaction and all others data.

SOMAVERT15mgpoudreetsolvantpourinjectable is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.

SOMAVERT15mgpoudreetsolvantpourinjectable
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	SOMAVERT15mgpoudreetsolvantpourinjectable
Availability	Prescription only
Generic	Pegvisomant
Pegvisomant Other Names	Pegvisomant
Related Drugs	octreotide, bromocriptine, Sandostatin, lanreotide, Somatuline Depot, Parlodel
Type
Formula	C₉₉₀H₁₅₃₂N₂₆₂O₃₀₀S₇
Weight	22129.0 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	France
Last Updated:	September 19, 2023 at 7:00 am

Uses

SOMAVERT15mgpoudreetsolvantpourinjectable is a growth hormone receptor antagonist used to treat acromegaly.

SOMAVERT15mgpoudreetsolvantpourinjectable is a growth hormone receptor antagonist used for the treatment of acromegaly.

SOMAVERT15mgpoudreetsolvantpourinjectable is also used to associated treatment for these conditions: Acromegaly

How SOMAVERT15mgpoudreetsolvantpourinjectable works

Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.